These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16086650)

  • 21. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
    Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dyslipidemia in HIV-infected individuals.
    Sprinz E; Lazzaretti RK; Kuhmmer R; Ribeiro JP
    Braz J Infect Dis; 2010; 14(6):575-88. PubMed ID: 21340298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.
    Floris-Moore M; Howard AA; Lo Y; Arnsten JH; Santoro N; Schoenbaum EE
    HIV Med; 2006 Oct; 7(7):421-30. PubMed ID: 16925727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Switching Between Antiretroviral Agents Versus Introducing Lipid-lowering Agents for HAART-induced Dyslipidemia.
    Mafumhe TF; Regalado G; Olojede SO; Lawal SK; Azu OO
    Clin Ther; 2024 Jun; 46(6):e114-e124. PubMed ID: 38851959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
    Hirsch HH; Battegay M
    Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
    Martínez E; Tuset M; Milinkovic A; Miró JM; Gatell JM
    Antivir Ther; 2004 Oct; 9(5):649-63. PubMed ID: 15535403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for management and treatment of dyslipidemia in HIV/AIDS.
    Sax PE
    AIDS Care; 2006 Feb; 18(2):149-57. PubMed ID: 16338773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals.
    Calmy A; Montecucco F; James RW
    Curr Vasc Pharmacol; 2015; 13(2):167-72. PubMed ID: 24188489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing cardiovascular risk in patients with HIV infection.
    Stein JH
    J Acquir Immune Defic Syndr; 2005 Feb; 38(2):115-23. PubMed ID: 15671795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical management considerations for dyslipidemia in HIV-infected individuals.
    Kirchner JT
    Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
    Rokx C; Verbon A; Rijnders BJ
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dyslipidemia and lipid management in HIV-infected patients.
    Lo J
    Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):144-7. PubMed ID: 21297466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation and management of dyslipidemia in patients with HIV infection.
    Green ML
    J Gen Intern Med; 2002 Oct; 17(10):797-810. PubMed ID: 12390557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
    Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
    BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.
    Calza L; Manfredi R; Chiodo F
    AIDS; 2003 Apr; 17(6):851-9. PubMed ID: 12660532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.
    Silverberg MJ; Leyden W; Hurley L; Go AS; Quesenberry CP; Klein D; Horberg MA
    Ann Intern Med; 2009 Mar; 150(5):301-13. PubMed ID: 19258558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic changes associated with antiretroviral therapy in HIV-positive patients.
    Almeida SE; Borges M; Fiegenbaum M; Nunes CC; Rossetti ML
    Rev Saude Publica; 2009 Apr; 43(2):283-90. PubMed ID: 19225696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.